The ROC curves and AUC values of the diagnostic model. by Zhe Wu (582498)

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. by Chengjun Yu (12136227)

ROC curve and AUC value of all models. by Tiago de Oliveira Barreto (20485207)

“…<div><p>Bed regulation within Brazil’s National Health System (SUS) plays a crucial role in managing care for patients in need of hospitalization. …”

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

“…<p>Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.…”

Force analysis of the system. by Jianbo Jia (717814)

Subjects:

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. by Guihua Wang (286390)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

Area under the curve (AUC) for external validation performance. by Junichi Kushioka (12236447)

Subjects:

The working principle of the Welleader system. by Jianbo Jia (717814)

Subjects:

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: